{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.5","upperLimit":"41.9","value":"19.0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.8","upperLimit":"66.0","value":"42.9"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"A response is defined to be a Complete Response (CR) or Partial Response (PR) noted as the objective status on any evaluation (i.e., best response). The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. A confidence interval for the true success proportion will be calculated according to the properties of the binomial distribution.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\n\n\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\n\n\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\n\n\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"OG000","title":"Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"up to 12 cycles","title":"Proportion of Responses (Complete Response or Partial Response)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}